PATHOS: a phase II/III trial of risk-stratified, reduced intensity adjuvant treatment in patients undergoing transoral surgery for Human papillomavirus (HPV) positive oropharyngeal cancer

Overview of attention for article published in BMC Cancer, August 2015

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (88th percentile)
High Attention Score compared to outputs of the same age and source (96th percentile)

Mentioned by

news: 1 news outlet
twitter: 5 X users

wikipedia: 1 Wikipedia page

Citations

dimensions_citation: 185 Dimensions

Readers on

mendeley: 200 Mendeley
citeulike: 1 CiteULike

Summary News X Wikipedia Dimensions citations

So far, Altmetric has seen 5 X posts from 5 X users, with an upper bound of 13,210 followers.

Apropos of this chat 💬 #pathos @NCRI_partners https://t.co/AKF0Ro357I

Reply Repost Favourite

RT @justinroe: @JoaquinJCabrera @BreastDocUK The PATHOS trial is phase II/III trial looking at reduced intensity adjuvant Tx: https://t.co/…

Reply Repost Favourite

@JoaquinJCabrera @BreastDocUK The PATHOS trial is phase II/III trial looking at reduced intensity adjuvant Tx: https://t.co/m0WsMAmDx7

Reply Repost Favourite

PATHOS: reduced intensity adjuvant treatment in pts undergoing transoral surgery for (HPV)+ oropharyngeal #cancer http://t.co/o9rhPBlKXD

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 1 additional X posts.